Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: Targeting both therapeutic modalities

Cancer Control

Volumn 16, Issue 2, 2009, Pages 153-157

  Fernandez, Hugo F ^a   Kharfan Dabaja, Mohamed A ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER RELAPSE; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DONOR LYMPHOCYTE INFUSION; EVENT FREE SURVIVAL; FOLLOW UP; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY; HUMAN; NEUTROPENIA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; REVIEW; SURVIVAL RATE; THROMBOCYTOPENIA; TIME; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 65249171992     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480901600207     Document Type: Review

References (39)

1. Giralt SA, Arora M, Goldman JM, et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol. 2007;137(5):461-467. Epub 2007 Apr 24.
2. Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2006;91(4):513-521. Epub 2006 Mar 1.
3. Cohen MH, Williams G, Johnson JR, et al. Approval summary for ima-tinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8(5):935-942.
4. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004.
5. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997;337(4):223-229.
6. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417.
7. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109(6):2303-2309. Epub 2006 Nov 30. Erratum in: Blood. 2007;110(5):1438.
8. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354 (24):2542-2551.
9. Rosti G, le Coutre P, Bhalla K, et al. A phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myel-ogenous leukemia (CML) in chronic phase (CP). J Clin Oncol. 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2007;25(18S June 20 suppl). Abstract 7007.
10. Kantarjian H, Cortes J. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices. J Natl Compr Canc Netw. 2008;6(suppl 2):S37-S42; quiz S43-S44.
11. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor ima-tinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2(2):117-125.
12. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96(3):1070-1079.
13. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352(9134):1087-1092.
14. Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med. 2003;349(15):1451-1464.
15. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk' chronic granulocytic leukemia. Blood. 1984;63(4):789-799.
16. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood. 2007;110(8):2828-2837. Epub 2007 Jul 12.
17. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6): 1809-1820. Epub 2006 May 18.
18. O'Brien S, Berman E, Bhalla K, et al. Chronic myelogenous leukemia. J Natl Compr Canc Netw. 2007;5(5):474-496.
19. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;99(10):3547-3553.
20. Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia. 2008;22(12):2176-2183. Epub 2008 Aug 28.
21. Wadhwa J, Szydlo RM, Apperley JF, et al. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood. 2002;99(7):2304-2309.
22. Wang Y, Wu D, Sun A, et al. Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis. Int J Hematol. 2008; 87(2):167-171. Epub 2008 Feb 22.
23. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resis-tant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354 (24):2531-2541.
24. Jabbour E, Cortes J, Kantarjian HM, et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood. 2006;108(4):1421-1423. Epub 2006 Apr 6.
25. Mohamed AN, Pemberton P, Zonder J, et al. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin Cancer Res. 2003;9(4):1333-1337.
26. Ruiz-Arguelles GJ, Tarin-Arzaga LC, Gonzalez-Carrillo ML, et al. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? Bone Marrow Transplant. 2008; 42(1):23-28.
27. Goldman JM. Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007. Bone Marrow Transplant. 2008;42(suppl 1):S11-S13.
28. Bittencourt H, Funke V, Fogliatto L, et al. Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase. Bone Marrow Transplant. 2008;42(9):597-600. Epub 2008 Aug 4.
29. Hehlmann R, Berger U, Pfirrmann M, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood. 2007;109(11):4686-4692. Epub 2007 Feb 22.
30. Appelbaum FR, Clift R, Radich J, et al. Bone marrow transplantation for chronic myelogenous leukemia. Semin Oncol. 1995;22(4):405-411.
31. Deininger M, Schleuning M, Greinix H, et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica. 2006;91(4): 452-459.
32. Oehler VG, Gooley T, Snyder DS, et al. The effects of imatinib mesy-late treatment before allogeneic transplantation for chronic myeloid leukemia. Blood. 2007;109(4):1782-1789. Epub 2006 Oct 24.
33. Weisser M, Schleuning M, Haferlach C, et al. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leuk Lymphoma. 2007;48(2):295-301.
34. Zaucha JM, Prejzner W, Giebel S, et al. Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2005;36(5):417-424.
35. Lee SJ, Kukreja M, Wang T, et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008;112(8):3500-3507. Epub 2008 Jul 29.
36. Kantarjian HM, O'Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myeloge-nous leukemia. Blood. 2002;100(5):1590-1595.
37. Hess G, Bunjes D, Siegert W, et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol. 2005;23(30):7583-7593.
38. Weisser M, Tischer J, Schnittger S, et al. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myeloge-nous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica. 2006;91(5):663-666. Epub 2006 Apr 19.
39. Savani BN, Montero A, Kurlander R, et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant. 2005;36(11):1009-1015.